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Abstract
The 5-HT1A/b-adrenoceptor ligand (¡)pindolol has been used in clinical trials to enhance the anti-
depressant eﬀect of selective serotonin (5-HT) reuptake inhibitors (SSRIs). The accelerating eﬀect of
(¡)pindolol is thought to derive from its blockade of the SSRI-induced, 5-HT1A autoreceptor-mediated
inhibition of serotonergic cell ﬁring and 5-HT release. However, controversial results have been reported
in regard to its ability to antagonize the eﬀect of 5-HT at such receptors. In the present study, we have
analysed the eﬀect of (¡)pindolol on receptor-mediated G-protein activation by measuring guanylyl
5k-[c-[35S]thio]-triphosphate ([35S]GTPcS) binding onto tissue sections from the hippocampus and dorsal
raphe nucleus from rat, guinea pig and human brain. In these regions, enriched in 5-HT1A receptors,
(¡)pindolol antagonized the stimulation of [35S]GTPcS binding induced by 5-HT in a concentration-
dependent manner. We found that in both rat and human brain the calculated pEC50 values were higher in
the dorsal raphe nucleus than in hippocampus. This suggests a higher potency of (¡)pindolol at somato-
dendritic 5-HT1A receptors compared to post-synaptic 5-HT1A sites. In the absence of 5-HT, (¡)pindolol
(up to 10x3 M) did not modify [35S]GTPcS binding, which remained at basal levels, indicating that, in this
assay, (¡)pindolol acts as a neutral antagonist rather than a partial agonist as it has been observed in other
experimental models. The present data are relevant for the understanding of the neurobiological basis of
pindolol acceleration of the action of SSRI antidepressants.
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Introduction
Since 1994, the b-adrenoceptor/5-HT1A/1B receptor
antagonist pindolol has been used to accelerate the
clinical eﬀects of antidepressant drugs acting primar-
ily on serotonergic neurons, such as the selective
serotonin (5-HT) reuptake inhibitors (SSRIs) (Artigas
et al., 1994). Pindolol is thought to act by preventing
the acute inhibition of 5-HT release and ﬁring of sero-
tonergic cells elicited by antidepressants, due to its
ability to antagonize the action of 5-HT at midbrain
raphe 5-HT1A autoreceptors (Artigas et al., 1996, 2001).
Hence, (x)pindolol (the active enantiomer at 5-HT1A
receptors) and racemic pindolol antagonize the re-
ductions in 5-HT release resulting from the activation
of 5-HT1A autoreceptors that follows the adminis-
tration of SSRIs and potentiates the elevation of the
extracellular concentration of 5-HT induced by these
drugs (Hjorth and Auerbach, 1994 ; Romero et al.,
1996). This view has been subsequently strengthened
by the observation that (x)pindolol antagonizes the
inhibitory eﬀects of 5-HT on dorsal raphe 5-HT-cell
ﬁring in vitro (Corradetti et al., 1998). More recently,
(x)pindolol has been shown to antagonize the actions
of 5-HT on guanylyl 5k-[c-[35S]thio]-triphosphate
(GTPcS) binding in rat brain and CHO cells trans-
fected with human 5-HT1A receptors, while displaying
a low intrinsic eﬃcacy (Newman-Tancredi et al., 1998,
2001). On the contrary, other reports suggest that pin-
dolol might act as a 5-HT1A receptor agonist because of
its ability to suppress 5-HT cell ﬁring in vivo (Cliﬀord
et al., 1998 ; Fornal et al., 1999b; Lejeune and Millan,
2000). Yet with one exception (Cliﬀord et al., 1998), this
eﬀect is not associated with a reduction of 5-HT release
in the forebrain (Dawson and Nguyen, 2000 ; Fornal
et al., 1999a; Romero et al., 1996).
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Moreover, a substantial discrepancy exists in regard
to the ability of pindolol to interact in a diﬀerential
manner with auto- and hetero-5-HT1A receptors. Pre-
vious studies have reported a preferential blockade of
the inhibitory action of 5-HT and 5-HT1A agonists at
presynaptic somatodendritic autoreceptors (Romero
et al., 1996 ; Tada et al., 1999), whereas others have
found a comparable eﬀectiveness at both receptor
populations (Corradetti et al., 1998) or an inability to
behave as a presynaptic 5-HT1A receptor antagonist
(Fornal et al., 1999b).
In-vitro autoradiographic studies have revealed
similar binding proﬁles of pindolol at pre- and post-
synaptic sites in the rodent, primate and human brain
(Raurich et al., 1999) or a slightly higher potency for
presynaptic sites in human (but not rodent) brain
(Castro et al., 2000). Interestingly, positron emission
tomography (PET) studies consistently showed a pref-
erential displacement of [11C]WAY-100635 frompre- vs.
post-synaptic 5-HT1A receptors in both rat and human
brain (Hirani et al., 2000 ; Martinez et al., 2001 ; Rabiner
et al., 2000).
The aim of the present study was to further explore
the actions of pindolol at 5-HT1A pre- and post-
synaptic sites in the rodent and human brain by
monitoring its eﬀects on [35S]GTPcS binding as a
measure of receptor-mediated G-protein activation.
Method
Adult male Wistar rats (200–250 g) and Dunkin–Hart-
ley Albino guinea pigs (250–300 g) were purchased
from Iﬀa Credo (Lyon, France). Animal care followed
the Spanish legislation on ‘Protection of animals
used in experimental and other scientiﬁc purposes’
in agreement with the European (EEC) regulations
(O.J. of EC L358/1 18/12/1986). The animals were kept
in a controlled environment (12-h light–dark cycle at
22¡2 xC), with free access to food and water. The
animals were sacriﬁced by decapitation, brains were
quickly removed, frozen on dry ice and kept at
x20 xC. Frozen human brain tissue samples were ob-
tained from the Neurological Tissue Bank, University
of Barcelona, Hospital Clinic (Barcelona, Spain) from
four women and two men (mean age 72 yr, range
60–78 yr, mean post-mortem delay 11 h, range 5–23 h)
without clinical or histopathological evidence of
neurological or psychiatric disease. The procedures
followed for using human brain samples were ap-
proved by the Ethical Committee of the Hospital
Clinic of Barcelona and the Bioethical Committee of
the Spanish Research Council (CSIC). Tissue sections,
10 mm thick, were cut using a microtome-cryostat
(HM500M, Microm, Walldorf, Germany), thaw-
mounted onto 3-aminopropyltriethoxysilane (APTS)-
coated slides and kept at –20 xC until use.
The autoradiographic procedure was essentially as
described previously (Dupuis et al., 1998 ; Sim et al.,
1995). The sections were pre-incubated twice in 50 mM
Hepes buﬀer (pH 7.4), containing 10 mM NaCl, 3 mM
MgCl2 and 0.2 mM EGTA for 15 min at room tem-
perature, the second time with the addition of 2 mM
GDP. Thereafter the sections were incubated for 1 h at
room temperature in the same buﬀer containing 2 mM
GDP, 0.2 mM dithiothreitol and 0.04 nM [35S]GTPcS
(1033 Ci/mmol ; Amersham, Little Chalfont, UK),
either in the absence or in the presence of agonist
and/or antagonist. Stimulation curves were generated
using 5-HT (10x10–10x4 M). Pindolol was used at con-
centrations ranging from 10x7 to 10x4 M either in the
presence or absence of 10 mM 5-HT. Basal [35S]GTPcS
binding was deﬁned in the absence of both agonist
and antagonist. The incubation was stopped by two
washes in ice-cold 50 mM Hepes buﬀer (pH 7.0). The
sections were dried with cold air and exposed to
Kodak X-OMAT (Kodak, Rochester, NY, USA) ﬁlms
during 2 wk for rat and guinea pig or 8 wk for human
tissue. Quantitative analysis of the autoradiograms
was performed with a computerized image analysis
system (MCID M4, St Catherine’s, Ontario, Canada)
using plastic 14C standards (American Radiolabeled
Chemicals, St Louis, MO, USA) which had been
exposed along with the labelled tissues. Inhibition
curves were statistically analysed using GraphPad
Prism software (GraphPad Software Inc., San Diego,
CA, USA).
Serotonin was purchased from Sigma (St Louis,
MO, USA) and (¡)pindolol from Research Biochemi-
cal International (Natick, MA, USA).
Results
In the presence of 2 mM GDP, 5-HT (10 mM) stimulated
[35S]GTPcS binding in sections from rat, guinea pig
and human hippocampus and dorsal raphe (Figure 1).
The maximal eﬀect of 5-HT in terms of per cent in-
crement of [35S]GTPcS binding relative to basal values
varied among regions, being most marked in the CA1
hippocampal ﬁeld (CA1), speciﬁcally in the layers or-
iens and radiatum in rat and guinea pig and in layers
oriens and pyramidale in humans. The response to 5-
HT was less marked in the dentate gyrus (molecular
layer) and entorhinal cortex and still weaker in the
dorsal raphe (2- to 4-fold lower than in CA1). The
apparent potencies (pEC50) displayed by 5-HT were
7.24¡0.17 and 6.88¡0.25 in the rat CA1 and dorsal
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raphe respectively, and 7.37¡0.18 and 7.06¡0.37 in
the human counterparts.
The stimulation induced by 5-HT in the aforemen-
tioned structures was completely antagonized by
(¡)pindolol in a concentration-dependent monophasic
manner (see Figures 1 and 2). As summarized in
Table 1, the pEC50 values displayed by (¡)pindolol
against 10 mM 5-HT varied depending on the brain re-
gion studied, the highest potency corresponding to the
dorsal raphe nucleus in the three species. Statistical
analysis (two-way ANOVA) performed on the pEC50
values obtained for (¡)pindolol showed a signiﬁcant
eﬀect of region factor (F3,26=8.649; p=0.000378).
Post-hoc Tukey t test indicated signiﬁcant diﬀerences
between dorsal raphe nucleus and the other regions.
Two-way ANOVA analysis (region, concentration) of
the inhibition curves taken as individual values re-
vealed a signiﬁcant eﬀect of region in human brain
(F3,54=7.477; p=0.0003) as well as region (F3,54=5.952;
p=0.0014), and regionrconcentration interaction
(F15,54=2.051 ; p=0.0279) in the rat brain. Post-hoc
Tukey t test indicated a statistically signiﬁcant diﬀer-
ence between dorsal raphe nucleus and hippocampal
structures in human and rat.
In the absence of 5-HT, (¡)pindolol on its own
did not modify [35S]GTPcS binding in the regions
Figure 1. Autoradiographic images from rat (A, B) and human (C, D) brain sections showing the distribution of [35S]GTPcS
labelling in the absence of agonist (basal binding, A1–D1), or in the presence of 10 mM 5-HT alone (A2–D2), 10 mM 5-HT and
100 mM (¡)pindolol (A3–D3), or 100 mM (¡)pindolol alone (A4–D4). Note that 5-HT-stimulated [35S]GTPcS binding is antagonized
by the addition of (¡)pindolol, whereas (¡)pindolol on its own is without eﬀect. CA1, CA1 hippocampal ﬁeld ; DG, dentate
gyrus ; DR, dorsal raphe; Ent, entorhinal cortex. (Bar, 3 mm.)
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analysed, which remained at basal levels (Figures 1
and 2).
Discussion
The present data show that (¡)pindolol inhibits 5-HT-
stimulated [35S]GTPcS binding in tissue sections from
rat, guinea pig and human brain in a concentration-
dependent manner. In both rat and human brain,
(¡)pindolol displays a slightly greater potency in the
dorsal raphe nucleus than in the hippocampus and
entorhinal cortex. On the other hand, pindolol behaves
as a neutral antagonist and does not stimulate
[35S]GTPcS binding in any of the species examined.
It is probable that the eﬀects of 5-HT upon
[35S]GTPcS binding, as well as the (¡)pindolol-
mediated inhibition reported here, are primarily medi-
ated through 5-HT1A receptors. This contention is
based on several previous observations. First, 5-HT1A
receptors are particularly enriched in the brain regions
showing high densities of 5-HT-stimulated [35S]GTPcS
binding, e.g. the dorsal raphe nucleus, the entorhinal
cortex or the hippocampus (Ko¨hler et al., 1986 ; Pazos
et al., 1987; Pazos and Palacios, 1985 ; Waeber et al.,
Table 1. pIC50 values of (¡)pindolol for 5-HT-stimulated
[35S]GTPcS binding to tissue sections
Rat
(pIC50¡S.E.M.)
Guinea pig
(pIC50¡S.E.M.)
Human
(pIC50¡S.E.M.)
CA1 5.11¡0.13 4.86¡0.10 4.98¡0.15
DG 4.89¡0.15 4.74¡0.20 5.36¡0.22
EntCx 4.56¡0.22 4.92¡0.23 5.02¡0.21
DR 5.41¡0.28** 5.60¡0.33 5.76¡0.31**
CA1, CA1 hippocampal ﬁeld ; DG, dentate gyrus ; EntCx,
entorhinal cortex ; DR, dorsal raphe.
(¡)Pindolol was used at concentrations ranging from 10x7 to
10x4 M. The concentration of 5-HT was 10 mM. [35S]GTPcS was
used at 0.04 nM. Data are mean¡S.E.M., n=3 (rat and guinea
pig) and n=6 (human) independent determinations.
Two-way ANOVA of pIC50 values obtained for (¡)pindolol
showed a signiﬁcant eﬀect of region factor (F3,26=8.649 ;
p=0.000378). Post-hoc Tukey t test indicated signiﬁcant
diﬀerences between DR nucleus and the other regions
(** p<0.01).
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Figure 2. Eﬀect of (¡)pindolol on basal (open symbols) and 5-
HT-stimulated (solid symbols) [35S]GTPcS binding to hippo-
campus (stratum radiatum of the CA1 ﬁeld in rat and guinea
pig or stratum pyramidale in human) (squares) and dorsal
raphe nucleus (DR) (circles) in rat, guinea pig and human
brain sections. Values are means¡S.E.M. obtained from three
(rat and guinea pig) or six (human) specimens, and are
expressed as percentage of the maximal binding obtained
with 10 mM 5-HT.
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1989a). It is of note that in the hippocampus the ana-
tomical pattern of 5-HT eﬀects was identical to the re-
gional and laminar distribution of 5-HT1A receptors
and clearly diﬀered from that of 5-HT1B/1D receptors
(Bruinvels et al., 1993, 1994). Secondly, in these re-
gions, [35S]GTPcS binding stimulated by 5-HT or 5-
HT1A selective and non-selective agonists is inhibited
by 5-HT1A antagonists such as WAY-100635, S15535
or NAN-190 (Dupuis et al., 1998 ; Newman-Tancredi
et al., 1999, 2001 ; Sim et al., 1997; Waeber and Mosko-
witz, 1997 ; Wang et al., 1997). Thirdly, (¡)pindolol is
known to have high aﬃnity (y10 nM) for this receptor
subtype (Hoyer and Schoeﬀter, 1991). Nonetheless,
since 5-HT can also stimulate [35S]GTPcS binding
through 5-HT1B receptors, and pindolol shows a simi-
lar aﬃnity for 5-HT1A and 5-HT1B receptors in the rat
brain (Hoyer and Schoeﬀter, 1991), the involvement of
the 5-HT1B subtype cannot be completely ruled out in
this species. However, given the negligible aﬃnity of
pindolol for human and guinea pig 5-HT1B receptors
(Hoyer et al., 1986 ; Metcalf et al., 1992 ; Parker et al.,
1993 ; Waeber et al., 1989b), these are unlikely to play a
signiﬁcant role in the reversal of the 5-HT-stimulated
[35S]GTPcS binding by pindolol.
The lack of an intrinsic action of pindolol on
[35S]GTPcS binding and its full reversal of the 5-HT
stimulatory eﬀects in all regions examined suggest
that, in the experimental conditions used, pindolol
behaves as a neutral antagonist. Following the clinical
observations on the acceleration of antidepressant ef-
fects of SSRIs by pindolol (see Introduction), its action
at 5-HT1A receptors has been scrutinized in the search
for possible novel mechanisms to improve the clinical
antidepressant action. Given the lack of selective 5-
HT1A receptor antagonists available for human use,
pindolol was used in clinical trials for its ability to
antagonize several responses induced by 5-HT1A
receptor agonists in rats and humans (Aulakh et al.,
1988 ; De Vivo and Maayani, 1990 ; Gehlbach and
Vandermaelen, 1987 ; Lesch et al., 1990; Tricklebank
et al., 1987). Interestingly, the agonist/antagonist
actions of pindolol depend to a large extent on the
experimental models used (see Artigas et al., 2001 for
review). Thus, pindolol has been shown to act as a
partial agonist at recombinant 5-HT1A receptors where
it elicits a modest activation of [35S]GTPcS binding
(Kobayashi et al., 1987 ; Pauwels et al., 1997). Consist-
ently, pindolol exhibits a low intrinsic eﬃcacy to in-
hibit adenylate cyclase in rat brain in vitro (De Vivo
and Maayani, 1990). However, and in agreement with
the present data, in a study using [35S]GTPcS auto-
radiography Newman-Tancredi et al. (2001) reported
a neutral antagonist action of pindolol in the rat brain.
These discrepancies may perhaps be explained by
diﬀerences in receptor density and/or coupling to
Gi/o proteins between transfected cells and tissue
sections, since the agonist character increases with re-
ceptor density in stable cell lines (Hoyer and Boddeke,
1993).
Similarly, the agonist/antagonist character of pin-
dolol at 5-HT1A receptors in vivo is largely contro-
versial (Artigas et al., 2001). When administered alone,
pindolol reduced 5-HT synthesis (Hjorth and Carls-
son, 1985) and 5-HT cell ﬁring in anaesthetized rats
(Sprouse et al., 2000) but failed to reduce 5-HT release
in the rat forebrain (Romero et al., 1996). Interestingly,
pindolol did not hyperpolarize 5-HT cells in the
dorsal raphe nucleus or CA1 hippocampal cells in the
slice preparation – an eﬀect mediated by 5-HT1A
receptors – and, in common with WAY-100635,
blocked 5-HT-induced hyperpolarizations (Corradetti
et al., 1998). Similarly, pindolol blocked the hyper-
polarization of dorsal raphe 5-HT cells induced by the
5-HT1A agonist gepirone (Gehlbach and Vandermae-
len, 1987). These electrophysiological observations
fully agree with the data from the present study and
give further support to the notion that pindolol be-
haves as a neutral antagonist at 5-HT1A receptors.
The discrepancy between these results and the sup-
pression of 5-HT cell ﬁring observed in vivomay lie in a
putative action at 5-HT1A receptors outside the dorsal
raphe nucleus. Although this possibility has not been
experimentally tested so far, it is supported by several
observations. First, more than one third of the dorsal
raphe 5-HT neurons are not inhibited by systemic
pindolol administration (Cliﬀord et al., 1998), despite
5-HT neurons expressing 5-HT1A autoreceptors (the
sensitivity to 8-OH-DPAT or selective 5-HT1A receptor
agonists is a basic criterion to identify a dorsal raphe
neuron as serotonergic). Secondly, a low dose of pin-
dolol antagonizes the inhibition of 5-HT cell ﬁring
produced by lysergic acid diethylamide (LSD), which
is thought to act preferentially on 5-HT1A auto-
receptors, but not that produced by 8-OH-DPAT agon-
ist at both pre- and post-synaptic 5-HT1A receptors
(Haddjeri et al., 1999). Finally, pre- and post-synaptic
5-HT1A receptors contribute to the suppression of
5-HT cell ﬁring and 5-HT release elicited by 5-HT1A
agonists (Casanovas et al., 1999 ; Ceci et al., 1994 ;
Celada et al., 2001 ; Hajos et al., 1999 ; Romero et al.,
1994). Thus, it cannot be dismissed that post-synaptic
5-HT1A receptors feeding back onto dorsal raphe
5-HT neurons via long loops may mediate the inhibit-
ory action of systemic pindolol.
The actions of pindolol at pre- and post-synaptic
receptors have been compared in a number of studies,
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also yielding controversial results (Castro et al., 2000;
Wieland and Chen, 1999). We have previously re-
ported that (x)pindolol exhibits comparable aﬃnities
for 5-HT1A receptors in the dorsal raphe and those lo-
cated in projection areas in diﬀerent species including
humans (Raurich et al., 1999). In contrast, a similar
study reported a slightly higher aﬃnity of (¡)pindolol
for 5-HT1A receptors of the dorsal raphe than for 5-
HT1A sites in the hippocampus in the human brain,
but not in the rat (Castro et al., 2000). In the present
study, the potency of pindolol to antagonize the eﬀect
of 5-HT in the dorsal raphe was higher than in struc-
tures receiving serotonergic innervation. Since the vast
majority of 5-HT1A receptors in the dorsal raphe are
located on 5-HT neurons (Sotelo et al., 1990) and only
a minor population appears to be expressed in non-
serotonergic cells (Kirby et al., 2003), the divergence
we observed is probably due to diﬀerences between
pre- and post-synaptic receptors. Thus, the diﬀerential
antagonism by pindolol may result from a higher
aﬃnity for presynaptic 5-HT1A autoreceptors, but also
could be a consequence of diversities in receptor–
G-protein coupling eﬃcacy and receptor reserve be-
tween 5-HT1A auto- and hetero-receptors. Pindolol has
also been reported to exert a selective antagonist ac-
tion at presynaptic 5-HT1A receptors (Romero et al.,
1996 ; Tada et al., 1999). Similarly, in PET scan studies,
pindolol administration results in a preferential occu-
pancy of pre- vs. post-synaptic 5-HT1A receptors both
in rat and human brain (Hirani et al., 2000; Martinez
et al., 2000). For instance, Rabiner et al. (2000) have
shown that, in humans, a single dose of pindolol
(10 mg) occupies approx. 37% of 5-HT1A receptors in
the dorsal raphe, whereas in other brain structures the
occupancy is only 13%. Similar results have been re-
ported by Martinez et al. (2000, 2001) using repeated
doses of pindolol (7.5 mg/d) during 1 wk. Therefore,
pindolol at the dose used in most clinical trials
(3r2.5 mg/d) (Artigas et al., 2001) seems to bind
predominantly to presynaptic 5-HT1A autoreceptors,
although reaching relatively low levels of occupancy.
Our results appear to indicate that 5-HT is slightly
more potent in the hippocampus than the dorsal
raphe, although regional diﬀerences in pEC50 did not
reach statistical signiﬁcance in our study. Such vari-
ations, although minor, could contribute to the prefer-
ential occupancy of dorsal raphe 5-HT1A receptors
observed in the aforementioned PET studies and
might also explain the diﬀerences in the apparent po-
tency of pindolol among regions.
An involvement of 5-HT receptor subtypes other
than 5-HT1A sites could also account for the diﬀerences
in the potency of pindolol between the dorsal raphe
and hippocampus found in the present study. In par-
ticular, 5-HT1B receptors are known to be present in
the dorsal raphe, and in the rat (but not in guinea pig
and humans), these are sensitive to pindolol. How-
ever, as discussed above, the contribution of other
5-HT receptor subtypes seems to be minor.
In summary, the present study indicates that
pindolol behaves as a neutral antagonist of 5-HT1A
receptors in vitro, as assessed with [35S]GTPcS auto-
radiography and inhibits the binding induced by
5-HT. The diﬀerent potency of pindolol between pre-
and post-synaptic sites is in keeping with some pre-
vious in-vivo and in-vitro data and may be related
to the preferential occupancy of midbrain vs. post-
synaptic 5-HT1A receptors observed in brain-imaging
studies. Overall, these results contribute to a better
understanding of the mechanisms involved in the
potentiation of antidepressant drug action by pindolol.
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